US 11,918,648 B2
Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer
Ying Yu, Palo Alto, CA (US); Andrew Evan Denker, Wynnewood, PA (US); Svetlana Sadekova, Palo Alto, CA (US); Uyen Truong Phan, Palo Alto, CA (US); Robert A. Kastelein, Palo Alto, CA (US); David Ross Kaufman, North Wales, PA (US); Robert L. Coffman, Berkeley, CA (US); Cristiana Guiducci, Berkeley, CA (US); and Robert S. Janssen, Berkeley, CA (US)
Assigned to MERCK SHARP & DOHME LLC, Rahway, NJ (US); and TRISALUS LIFE SCIENCES, INC., Westminster, CO (US)
Filed by MERCK SHARP & DOHME LLC, Rahway, NJ (US); and TRISALUS LIFE SCIENCES, INC., Westminster, CO (US)
Filed on Aug. 21, 2020, as Appl. No. 17/000,149.
Application 17/000,149 is a continuation of application No. 15/577,369, granted, now 10,751,412, issued on Aug. 25, 2020, previously published as PCT/US2016/034275, filed on May 26, 2016.
Claims priority of provisional application 62/169,309, filed on Jun. 1, 2015.
Claims priority of provisional application 62/168,449, filed on May 29, 2015.
Prior Publication US 2021/0196819 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 31/7115 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/435 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/395 (2013.01) [A61K 31/7115 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/435 (2013.01); C07K 16/244 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55561 (2013.01); A61K 2300/00 (2013.01); C07K 2317/76 (2013.01)] 9 Claims
 
1. A method for treating cancer in an individual comprising administering to the individual a combination therapy which comprises a PD-1 antagonist and a TLR9 agonist, wherein:
the PD-1 antagonist is a monoclonal antibody, or antigen binding fragment thereof, which comprises: (a) light chain CDRs of SEQ ID NOs: 1, 2 and 3 and heavy chain CDRs of SEQ ID NOs: 4, 5 and 6; or (b) light chain CDRs of SEQ ID NOs: 7, 8 and 9 and heavy chain CDRs of SEQ ID NOs: 10, 11 and 12; and
the TLR9 agonist is a CpG-C type oligonucleotide, wherein the CpG-C type oligonucleotide comprises 5′-TCG Nq TTCGA ACG TTC GAA CGT TCG AAT-3′ (SEQ ID NO: 66), wherein N are nucleosides and q=4.